Comparison of Clorotekal and Bupivacaine for Short Obstetric Surgery
Launched by OREGON HEALTH AND SCIENCE UNIVERSITY · May 26, 2019
Trial Information
Current as of August 21, 2025
Suspended
Keywords
ClinConnect Summary
This will be a single-blind, randomized, controlled, single center clinical trial assessing the efficacy of spinal chloroprocaine on resolution of motor block and associated patient flow through the post-anesthesia care unit . Fifty patients will be equally randomized to receive either spinal chloroprocaine or hyperbaric bupivacaine.
Masking:
1. Subject
2. Obstetric provider
3. Investigator
4. Outcomes assessor
The anesthesia provider will be unblinded.
Subjects will be allocated to either intrathecal injection of 50 mg of 1% chloroprocaine or 10.5 mg (1.4 mL) of 0.75% hyperbaric bupiva...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Women 18 years old to 60 years old
- • 2. American Society of Anesthesiologists physical status class 1-3
- • 3. Undergoing one of the following obstetric procedures: bilateral tubal ligation, external cephalic version, cerclage insertion, cerclage removal, minimally invasive fetal surgery, or evacuation of retained products of conception.
- Exclusion Criteria:
- • 1. Refusal of consent
- • 2. Multiple gestations
- • 3. History of ester local anesthetic or para-aminobenzoic acid allergy
- • 4. Height less than 5 feet or greater than 6 feet
- • 5. Body mass index less than 18.5 kg/m2 or greater than 45 kg/m2
- • 6. Any coagulopathy defined by platelets \< 80k/microliter, International Normalized Ratio \> 1.2, or Partial Thromboplastin Time \> 36 seconds
- • 7. Signs of hypovolemia that is not corrected by routine management including hypotension (systolic blood pressure \< 90 mm Hg) at the time of evaluation
- • 8. Liver disease including jaundice and ascites, with elevated liver function tests, Aspartate Aminotransferase \> 2x institutional normal, Alanine Aminotransferase \> 2x institutional normal
- • 9. Renal disease including history of dialysis, with elevated renal function tests on admission labs, glomerular filtration rate \< 60 ml/min/1.73 m2
- • 10. Infection at the site of potential spinal insertion
- • 11. Neurologic condition that contraindicates spinal anesthesia, tethered spinal cord or multiple sclerosis
- • 12. Known atypical plasma cholinesterase activity
- • 13. Other contraindications to receive a spinal anesthetic
- • 14. Vulnerable populations including prisoners and decisionally impaired adults
About Oregon Health And Science University
Oregon Health and Science University (OHSU) is a leading academic medical center dedicated to advancing health through research, education, and patient care. As a prominent sponsor of clinical trials, OHSU leverages its extensive expertise in various medical fields to facilitate innovative research aimed at improving patient outcomes. The institution is committed to ethical standards and rigorous scientific methodologies, fostering collaborations that enhance the development of new therapies and interventions. With a focus on translating research discoveries into clinical practice, OHSU plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Portland, Oregon, United States
Patients applied
Trial Officials
Brandon M Togioka, MD
Principal Investigator
Oregon Health and Science University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials